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Abstract: A myriad of factors favor the emergence and re-emergence of arthropod-borne 
viruses  (arboviruses),  including  migration,  climate  change,  intensified  livestock 
production, an increasing volume of international trade and transportation, and changes to 
ecosystems  (e.g.,  deforestation  and loss  of  biodiversity).  Consequently,  arboviruses  are 
distributed  worldwide  and  represent  over  30%  of  all  emerging  infectious  diseases 
identified  in the past decade.  Although some  arboviral infections  go undetected or  are 
associated  with  mild,  flu-like  symptoms,  many  are  important  human  and  veterinary 
pathogens  causing  serious  illnesses  such  as  arthritis,  gastroenteritis,  encephalitis  and 
hemorrhagic fever and devastating economic loss as a consequence of lost productivity and 
high mortality rates among livestock. One of the most consistent molecular features of 
emerging  arboviruses,  in  addition  to  their  near  exclusive use  of  RNA  genomes,  is  the 
inclusion of viral, non-structural proteins that act as interferon antagonists. In this review, 
we describe these interferon antagonists and common strategies that arboviruses use to 
counter the host innate immune response. In addition, we discuss the complex interplay 
between host factors and viral determinants that are associated with virus emergence and 
re-emergence, and identify potential targets for vaccine and anti-viral therapies. 
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1. Introduction  
Arthropod-borne viruses (arboviruses) are a large group of viruses that use hematophagous (blood 
feeding) arthropod vectors, including mosquitoes, ticks, biting midges, and phlebotomine flies, for 
transmission  between  vertebrate  hosts.  Arboviruses  come  from  numerous  viral  families,  including 
Togaviridae  (genus  Alphavirus);  Bunyaviridae  (genera  Nairovirus,  Orthobunyavirus,  and 
Phlebovirus);  Flaviviridae  (genus  Flavivirus);  Rhabdoviridae  (genus  Vesiculovirus); 
Orthomyxoviridae  (genus  Thogotovirus);  Reoviridae  (genus  Orbivirus);  and  Asfarviridae  (genus 
Asfarvirus) [1,2]. In addition, a diverse group of arthropod-vectored plant viruses have been described 
including  members  of  the  Bunyaviridae  (genus  Tospovirus);  Geminiviridae  (genera  Mastrevirus, 
Curtovirus,  Begomovirus,  and  Topocuvirus);  Caulimoviridae  (genera  Badnavirus,  Caulimovirus, 
Tungrovirus, and Soymovirus); Potyviridae (genera Potyvirus, Rymovirus, Macluravirus, Ipomovirus, 
and Tritimovirus); and Closteroviridae (genera Closterovirus, Crinivirus, and Ampelovirus). However, 
because they do not infect vertebrates, these arthropod-vectored plant viruses are not classified as 
arboviruses [3–5]. Remarkably, arboviruses have the ability to infect a broad range of vertebrate hosts, 
which is important for their maintenance and amplification in nature; these amplifying vertebrate hosts 
achieve a high viremia that enables transmission of the virus to a naïve arthropod taking a blood meal. 
Despite this high viremia, most amplifying hosts do not typically show overt signs of disease because 
of these infections.  
In most instances, humans serve as dead-end hosts and do not participate in the maintenance of 
arbovirus lifecycles. Unlike amplifying hosts, humans and other dead-end hosts can develop disease 
caused by arboviral infection. Although many arboviral infections in humans are asymptomatic or 
result in a mild influenza-like illness, some arboviruses can cause respiratory illness, arthritis, febrile 
illness, encephalitis, hemorrhagic syndrome, shock, and/or death. Therefore, several arboviruses have 
become  increasingly  important  human  and  veterinary  pathogens,  representing  nearly  30%  of  all 
emerging  infectious  diseases in  the  last  decade  [6].  In  this  review,  part  of  a  special  issue  on  the 
pathogenesis of emerging and re-emerging RNA viruses, we will focus on members of the genera 
Flavivirus and Alphavirus and the family Bunyaviridae and the role of their nonstructural proteins in 
antagonizing the host interferon (IFN) response. 
2. Emergence  
Arthropod vectors are both direct and indirect factors in the emergence and re-emergence of many 
arboviruses. The sylvatic transmission cycle between the invertebrate vector(s) and vertebrate reservoir 
not only allows for the maintenance and amplification of the arboviruses, but also contributes to their 
emergence.  In  addition,  climate  plays  a  critical  role  in  determining  the  transmission  patterns  for 
arboviruses. The virus can either circulate throughout most of the year with broad seasonal peaks in 
tropical areas or, in a more temperate climate, it can be transmitted between vectors and vertebrates Viruses 2011, 3                         
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during the warmer months while overwintering in mosquito eggs [7]. In these temperate climates, 
arboviral  disease  is  absent  during  the  colder  months.  Longer  periods  of  warm  weather  not  only 
lengthen the seasonal peaks of virus circulation, but also provide conditions conducive to increasing 
vector  populations.  Climate  change  is  thought  to  exacerbate  the  emergence  and  re-emergence  of 
arboviruses dependent on these periods of warm weather and provide opportunities for changes in 
vector range, vertebrate host and vector composition [1,8].  
Human behavior influences arthropod vectors in a variety of ways that contribute to the emergence 
and re-emergence of arboviruses. Urban sprawl, population growth, and agricultural development have 
increased  human  contact  with  arboviral  vectors.  Population  growth  and  urbanization  have  led  to 
crowded living conditions and provided ideal breeding sites for mosquitoes owing to the inadequate 
management  of  water  and  waste,  further  increasing  the  intersection  of  dense  human  and  vector 
populations. Globalization, including modern travel and trade, has facilitated the spread of arboviruses 
and the anthropophilic mosquitoes, including Aedes aegypti, Aedes albopictus, and mosquitoes in the 
Culex pipiens complex, which have the potential to introduce arboviruses into a naïve population of 
vertebrate  hosts  [9,10].  Although  the  spread  of  arboviruses  linked  to  travel  has  not  been  directly 
attributed to infected humans seeding the virus in naïve populations, this possibility/scenario is of 
growing concern because some arboviruses have been able to adapt to an urban epidemic cycle in 
which humans have become the primary amplifying host; an urban epidemic cycle has been described 
for dengue virus (DENV), yellow fever virus (YFV), and chikungunya virus (CHIKV) [11–14]. The 
worldwide distribution and potential for emergence of arboviruses along with the paucity of effective 
vaccines and therapeutics underscores the importance of these viruses in the increasingly globalized 
human population. 
3. Interferon Responses to Viral Infection 
With the exception of the Asfarviridae, a family of DNA viruses that replicate in ticks (its role in 
countering  the  innate  immune  system  is  reviewed  in  [15]),  arboviruses  are  single  stranded  RNA 
viruses. Type I IFNs are induced by dsRNA as well as viral RNA containing 5’-triphosphates and it 
has been demonstrated that many arboviruses induce an IFN response shortly following delivery from 
their arthropod vector. The initial interaction between viruses and the innate immune system plays a 
major role in determining whether the virus will successfully establish infection. To counter the host 
immune response, many arboviruses encode nonstructural as well as some structural proteins like the 
capsid of the equine encephalitis viruses, that function, in part, to antagonize the host IFN response 
[16,17]. The focus of this review will solely be on the nonstructural proteins of arboviruses that serve 
as IFN antagonists (Table 1). This adaptation has enhanced the ability of these viruses to establish 
themselves  in  a  multitude  of  vertebrate  hosts  and  plays  an  important  role  in  their  emergence. 
Importantly, a greater understanding of how these arboviral nonstructural proteins counter the host 
immune  response  may  lead  to  the  development  of  attenuated  vaccines  and/or  antiviral  therapies. 
Accordingly, arboviral nonstructural proteins that counteract IFNs are the focus of this review.  
The rapid production of IFNs and other cytokines are important components of the innate immune 
response  against  viral  infections  and  ultimately,  the  clearance  of  the  infection.  In  the  cell,  IFN 
induction due to cytoplasmic signaling cascades triggered by the detection of viral components and the Viruses 2011, 3                         
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resulting IFN-/ induces an antiviral state alleviating virus burden and initiating an adaptive immune 
response. For RNA viruses to replicate, viral genomic RNA must be unwrapped from the nucleocapsid 
and  exposed  to  allow  for  viral  transcription/translation.  However,  exposed  viral  RNA  provides  a 
reliable substrate for cells to sense a viral infection. Both retinoic acid-inducible gene I (RIG-I) and 
melanoma  differentiation-associated  gene  5  (MDA5)  are  cytoplasmic  proteins  that  recognize  viral 
components in the cytosol. RIG-I preferentially binds 5’-phosphorylated ssRNA and short dsRNA while 
MDA5 does not require 5’-phosphorylation and is activated by higher-order structured RNA containing 
ssRNA or dsRNA [18–25]. MDA5 and RIG-I signal through mitochondrial membrane-associated INF- 
promoter stimulator 1 (IPS-1). Subsequently, tumor necrosis factor (TNF) receptor-associated factor 3 
(TRAF3) activates TANK-binding kinase 1 (TBK1) and inhibitor of nuclear factor kappa B (NF-B) 
kinase  (IKK). TBK1 and IKK phosphorylate IFN regulatory factor 3 (IRF-3) and IRF-7, which 
translocate into the nucleus where they bind IFN-stimulated response elements (ISREs) resulting in 
type I IFN expression, namely IFN- and IFN-4 as early type I IFNs (Figure 1) [26–28].  
Additionally, mammalian cells use transmembrane proteins known as toll-like receptors (TLRs) to 
sense pathogen-associated molecular patterns. There are 10 members of the TLR family in humans and 
each one is capable of detecting a specific pathogen-associated molecular pattern  [29–31].  TLR3, 
TLR7, TLR8, and TLR9 are the main viral sensors and they are located on the cell surface (TLR3) or 
in endosomal compartments (TLR3, TLR7, TLR8, and TLR9). TLR7 and TLR8 detect ssRNA. The 
specificity of the dsRNA receptor TLR3 allows it to recognize genomes of dsRNA viruses as well as 
replicative intermediates of ssRNA viruses [32–36]. Unmethylated CpG-containing DNA, a common 
component in the genomes of DNA viruses, is recognized by TLR9 [37]. TLR7, TLR8, and TLR9 
signal through the MyD88 adapter leading to activation of type I IFNs and NF-B signaling, while 
TLR3  signals  through  the  adapter  protein  TIR  domain-containing  adapter-inducing  IFN-  (TRIF) 
which results in type I IFN induction (Figure 1) [38].  
Two other cellular sensors are protein kinase R (PKR) and 2’,5’-oligoadenylate synthetase (OAS). 
PKR dimerizes upon binding dsRNA and subsequently phosphorylates eukaryotic initiation factor 2- 
(eIF2-) preventing viral replication by inhibition of translation and activates NF-B by degradation 
of IB [39]. 2’,5’-OAS is activated by dsRNA initiation ultimately leading to activation of RNase L, 
an endoribonuclease, to degrade RNA [40]. Importantly, many of these viral sensors are up-regulated 
in response to type I IFNs.  
Early  type  I  IFNs  bind  to  cell  surface  IFN-/  receptors  (IFNARs),  which  are  heterodimers 
composed of two subunits, IFNAR1 and IFNAR2 (Figure 1) [41]. The janus kinases Tyk2 and Jak1 are 
associated with the cytoplasmic tails of IFNARs and are activated by IFN binding to its receptor  
[42–44]. Subsequently, STAT2 is recruited by phosphorylated tyrosine residues on the IFNAR and 
becomes  phosphorylated  (pSTAT2)  [45].  Active  pSTAT2  recruits  and  phosphorylates  STAT1 
(pSTAT1)  [46].  pSTAT1  and  pSTAT2  heterodimerize  and  complex  with  IRF-9,  forming  the 
transcription factor complex IFN-stimulated gene factor 3 (ISGF3), which translocates to the nucleus 
activating ISREs [47–49]. These ISREs are within upstream promoter regions of IFN-stimulated genes 
(ISGs) and regulate their expression. ISGs include viral pattern recognitions receptors such as RIG-I, 
MDA5,  TLRs,  2’,5’-OAS,  PKR;  transcription  factors  such  as  STAT1,  STAT2,  IRF3  as  well  as 
antiviral effectors such as Mx and Ifit family members that are important for the control of viral 
infection. Thus, viruses use numerous strategies to antagonize the IFN response since expression of Viruses 2011, 3                         
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ISGs is critical in limiting viral replication. These strategies used by arboviruses will be discussed in 
the context of bunyavirus, alphavirus, and flavivirus nonstructural proteins.  
Table 1. Direct and indirect interferon antagonist functions of arboviral nonstructural proteins. 
Family 
Nonstructural 
Proteins  Direct IFN Antagonism 
Host Transcriptional 
Shut off as Indirect 
Mechanism for IFN 
Antagonism 
References    Genus 
  Virus 
Bunyaviridae         
  Orthobunyavirus         
  La Crosse virus  NSs   
-Inhibits RNA Pol II 
transcription by 
triggering degradation of 
RPB1 
[72] 
  Bunyamwera 
virus  NSs   
-Inhibits RNA Pol II 
transcription by blocking 
elongation 
[84,85] 
  Phlebovirus         
  Rift Valley Fever 
virus  NSs 
-Degrades PKR 
-Interacts with SAP30 to 
block activation of the 
IFN- promoter 
-Inhibits RNA Pol II 
transcription by 
preventing TFIIH 
assembly 
[78,83,100] 
Togaviridae         
  Alphavirus         
 
Venezuelan 
Equine 
Encephalitis virus 
nsP2?  -Blocks STAT1 
phosphorylation 
-Transcriptional shutoff 
by capsid protein  [17,111] 
  Chikungunya 
virus  nsP2  -Blocks STAT1 nuclear 
import 
-Transcriptional shutoff 
(mechanism unknown)  [113,115] 
  Sindbis virus  nsP2 
-Blocks NF-B-
dependent PRDII 
promoters? 
-Downregulation of RNA 
Pol I and II-dependent 
transcription 
[16,118] 
  Semliki Forrest 
virus  nsP2  -Cleavage of transcription 
factors (suggested) 
-Transcriptional shutoff 
(mechanism unknown)  [16,120] 
  Ross River virus  nsP1  -Block IRF-3?    [124] 
Flaviviridae         
  Flavivirus         
  Langat virus  NS5 
-Blocks STAT1 
phosphorylation by 
interaction with 
IFNAR2/IFNGR1 
  [132] 
  Tick-borne 
Encephalitis virus   NS5 
-Blocks STAT1 
phosphorylation by a 
mechanism involving 
interactions with hScrib 
  [131] 
  Dengue virus  NS5 
-Blocks STAT2 
phosphorylation 
-Degrades STAT2 
  [133,134] 
    NS4B 
-Unknown but requires 
localization and insertion 
into ER membrane 
  [135] 
    NS2A/NS4A  -Unknown    [135] 
  Japanese 
Encephalitis virus  NS5 
-Blocks STAT1 and Tyk2 
phosphorylation by 
activating PTP(s) 
  [145] 
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Figure 1. Arbovirus nonstructural proteins use several mechanisms to disrupt IFN induction and signaling. (A) The Toll-like receptor (TLR) 
family  members,  TLR3,  TLR7,  TLR8,  and  TLR9  are  located  in  endosomal  membranes  sensing  double-stranded  RNA  (dsRNA),  
single-stranded RNA (ssRNA), and CpG DNA ligands, respectively, in the endosomes. TLR7, TLR8, and TLR9 signal through the MyD88 
adapter ultimately leading to production of type I IFNs and inflammatory cytokines. TLR3 uses the adapter protein Toll/interleukin-1 (IL-1) 
receptor (TIR) domain-containing adapter-inducing IFN-β (TRIF) inducing production of type I IFNs. Retinoic acid-inducible gene I (RIG-I), 
melanoma differentiation-associated gene 5 (MDA5) and double-stranded RNA-dependent protein kinase (PKR) detect viral products in the 
cytosol. Both MDA5 and RIG-I signal through the mitochondrial-membrane-associated IFN-β promoter stimulator 1 (IPS1) resulting in 
activation of IRF3 and IRF7. (B) Secreted IFN-α/β binds in an autocrine or paracrine fashion to cell surface IFN-α receptors (IFNAR). 
Subsequently, JAK-STAT signaling leads to phosphorylation and dimerization of signal transducer and activator of transcription 1 (STAT1) 
and STAT2, the formation of the IFN-stimulated gene factor 3 (ISGF3) complex and its translocation to the nucleus. Here, ISGF3 binds to 
IFN-stimulated response elements (ISREs) and initiates transcription of IFN-stimulated genes (ISGs). Bunyavirus NSs (nonstructural protein 
encoded  by  the  S  segment)  targets  the  activities  of  RNA  polymerase  II  and  many  other  arboviruses  inhibit  JAK-STAT  signaling. 
Nonstructural proteins can cause the degradation of some of the components involved in these pathways. Although not the focus of this 
review, other arboviral proteins, including New World alphavirus capsid proteins, can also play a role in IFN antagonism. 
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4. Bunyaviruses 
Five genera (Orthobunyavirus, Hantavirus, Nairovirus, Phlebovirus, and Tospovirus) make up one 
of the largest and most diverse viral families, the Bunyaviridae [50]. Bunyaviruses are disseminated 
worldwide and infect a broad range of invertebrate and vertebrate hosts. With the exception of the 
hantaviruses  [51],  all  of  the  genera  within  the  Bunyaviridae  are  vector-borne  [50].  While  the 
tospoviruses are plant pathogens, the majority of bunyaviruses are significant pathogens in humans and 
animals. Notably, Crimean-Congo hemorrhagic fever virus (CCHFV; Nairovirus), La Crosse virus 
(LACV; Orthobunyavirus), and Rift Valley fever virus (RVFV; Phlebovirus) are important human 
pathogens  causing  disease  ranging  from  mild,  febrile  illness  to  more  severe  disease  including 
pulmonary disease, hemorrhagic fever, and fatal encephalitis [52,53]. The potential for emergence of 
these  viruses  is  demonstrated  by  CCHFV,  which  is  the  second  most  widespread  of  all  medically 
important arboviruses after DENV and is endemic in much of Africa, Asia, and Europe [54,55]. With 
the exception of vaccines for veterinary use to protect against RVFV, there are currently no effective 
therapeutics or vaccines for bunyaviruses.  
The bunyavirus genome consists of three single-stranded, negative-sense RNA segments designated 
by size as large (L), medium (M), and small (S). The L segment encodes the viral polymerase. A 
polyprotein,  encoded  in  a  single  open  reading  frame  by  the  M  segment,  is  post-translationally 
processed into the viral glycoproteins, Gc and Gn, and in the case of the orthobunyaviruses and some 
phleboviruses,  a  nonstructural  protein  (NSm)  of  unknown  function.  The  S  segment  encodes  the 
nucleocapsid  protein  (N).  For  three  bunyavirus  genera,  the  S  segment  also  encodes  another 
nonstructural  protein  (NSs)  through  an  overlapping  reading  frame  in  most,  but  not  all, 
orthobunyaviruses  or  an  ambisense  coding  mechanism  (phleboviruses  and  tospoviruses)  [56,57]. 
Interestingly, there is a clear divergence among the bunyaviruses delineated by the presence or absence 
of  NSs.  Bunyaviruses  that  use  insects  as  their  vectors  (orthobunyaviruses,  phleboviruses,  and 
tospoviruses) encode NSs proteins while those bunyaviruses that use non-insect vectors (nairoviruses) 
or  are  not  vector-borne  (hantaviruses)  do  not  encode  NSs  proteins  (Figure  2).  The  bunyavirus 
maintenance  and  amplification  cycles,  alternating  between  insect  vectors  and  vertebrate  hosts, 
demonstrates this group’s ability to adapt and take advantage of the host immune system. For example, 
while LACV infection in insect cells is noncytolytic and leads to long-term viral persistence, it causes 
host  cell  gene  expression  shutoff  at  the  level  of  transcription  and  cell  death  in  mammalian  cells 
resulting in cell lysis or cell death [58,59]. Mosquitoes, as well as other insects, have an effective 
innate immune system comprised of three major signaling pathways, the Toll, the Immune Deficiency 
(imd), and the JAK-STAT pathways [60–64]. When LACV-directed siRNAs against the L, M, or S 
segments  were transfected into mammalian 293T and  insect  C6/36 cells, the  siRNA targeting the 
LACV S segment was the most effective inhibitor of virus replication in both cell types [65]. These 
data suggest a conserved function of NSs in both mammalian and insect cells. We speculate that if the 
NSs inhibits the JAK-STAT pathway in insects, then the virus may be able to sustain an infection. 
Furthermore,  the  absence  of  cytolytic  infection  in  insect  cells  and  the  lack  of  adaptive  immune 
responses in insects may allow the virus to persist in its insect hosts. However, bunyaviruses lacking 
NSs protein avoid RIG-I activation by removing the 5’-triphosphates from their genomes to avoid IFN Viruses 2011, 3                         
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induction [66]. Therefore, viruses lacking a NSs may not have been subject to the same selective 
pressure to express a potent IFN antagonist.  
Figure 2. Phylogeny of arthropod vectors used by the Bunyaviridae. Bunyaviruses whose 
life cycle includes an insect vector (phleboviruses, orthobunyaviruses, and tospoviruses) 
encode a NSs protein either through an ambisense coding mechanism or in a reading frame 
that overlaps with that of the nucleocapsid (N). In contrast, bunyaviruses that do not use 
insect vectors (nairoviruses and hantaviruses) lack a NSs protein.  
 
4.1. Orthobunyaviridae: La Crosse Virus (LACV) and Bunyamwera Virus (BUNV) 
Within  the  Orthobunyavirus  genus,  the  California  serogroup  consists  of  14  viruses  that  are 
antigenically related to its type species, California encephalitis virus. Some members of the California 
serogroup can lead to neuronal infection and encephalitis following peripheral infection in mice and 
humans [50,67]. LACV is the most studied of the California serogroup and is an emerging cause of 
pediatric encephalitis and aseptic meningitis in the American South [68,69]. While cases of LACV 
encephalitis have historically occurred in the midwestern United States, LACV activity has risen above 
endemic  levels  in  the  southeastern  United  States  including  West  Virginia,  North  Carolina,  and 
Tennessee [68]. The isolation of LACV from Ae. albopictus mosquitoes in Texas has led to growing 
concern since the virus has adapted from this invasive mosquito species [70].  
The  LACV  NSs  suppresses  the  type  I  IFN  system  in  mammalian  cells  [71]  and  the  use  of  a 
recombinant LACV mutant lacking NSs (rLACVNSs) has provided an important tool in determining 
the role of NSs in LACV pathogenesis. Infecting insect cells with rLACVNSs, Blakqori et al. [71] 
demonstrated  that  NSs  is  not  required  for  infection  or  virus  growth,  and  does  not  inhibit  RNAi. 
However, in IFN-competent mouse embryonic fibroblasts, rLACVNSs strongly induces transcription 
of  the  IFN-  gene  while  wild-type  recombinant  LACV  (WT  rLACV)  does  not  as  measured  by  
RT-PCR. IFN induction by LACV mainly occurs through the signaling pathway initiated by RIG-I 
[72]. Furthermore, mouse embryonic fibroblasts lacking the IFNAR (IFNAR −/−) still produced IFN- Viruses 2011, 3                         
 
 
637 
following infection with rLACVNSs, demonstrating that IFN induction is a direct result of virus 
infection and not due to secreted IFN [71]. While there was no quantitation of the RT-PCR provided, 
the LACV N gene showed that viruses replicated to similar levels, cellular -actin mRNA indicated 
similar amounts of RNA in the preparations and it appears the IFN- gene was equally activated in 
both WT and IFNAR−/− mouse embryonic fibroblasts when infected with rLACVNSs. The authors 
confirmed that the block in IFN induction is solely due to NSs by transfecting human 293 cells with a 
NSs-expressing  plasmid  and  an  IFN-  promoter  reporter  plasmid.  The  cells  were  stimulated  with 
synthetic dsRNA and LACV NSs potently inhibited the induction of the IFN- promoter in response to 
dsRNA.  Additionally,  in  both  cell  culture  and  mice,  wt  rLACV  had  a  growth  advantage  over 
rLACVNSs  that  was  abrogated  in  IFNAR  −/−  mouse  embryonic  fibroblasts  and  mice  [71]. 
Therefore, NSs is only important in IFN-competent mammalian hosts and the lack of the LACV NSs 
gene can be compensated for by the inactivation of the host’s IFN system. Importantly, brains of mice 
infected with rLACVNSs induced significantly higher IFN- and IFN- transcripts than WT rLACV 
demonstrating that IFN antagonism by NSs of LACV is also functional in neurons and may play a 
critical role in the neuropathogenesis of LACV infection [71]. Importantly, both viruses (WT rLACV 
and rLACVNSs) preferentially infected neurons and no viral antigen was detected in GFAP positive 
astrocytes,  oligodendrocytes,  or  macrophages  [71]  suggesting  the  neurons  are  responsible  for  the 
production of IFN- and IFN- in the central nervous system (CNS) of LACV infected mice.  
The growth advantage of WT rLACV over rLACVNSs in immunocompetent mouse embryonic 
fibroblasts and mice [71] may demonstrate the selective pressure on LACV by the host IFN system to 
develop measures to counteract the IFN response. The evolution of LACV NSs IFN suppression not 
only provides a growth advantage to LACV, but it contributes to the pathogenesis of LACV as well. 
By disabling the IFN response, LACV can replicate more efficiently in cells and prevent the antiviral 
state of other cells, providing additional rounds of viral replication. Ultimately, this strategy allows 
LACV  to  grow  to  a  higher  titer in  the  peripheral tissue  resulting  in  its  neuroinvasive  phenotype. 
Therefore,  if  LACV  were  to  evolve  an  additional  mechanism  of  IFN  antagonism  to  work 
synergistically  with  the  current  mechanism  of  LACV  NSs  the  result  could  lead  to  higher  risk  of 
neurological disease by allowing more efficient peripheral replication and/or more severe neurological 
disease once LACV has reached the CNS.  
In the mouse model of LACV encephalitis, a high percentage of WT mice succumbed to LACV 
infection even when rLACVNSs was used [71], demonstrating that deletion of NSs was not sufficient 
to completely attenuate LACV in vivo. The authors speculated that this is because the mice lacked a 
suitable IFN-induced antiviral effector activity. More specifically, human MxA protein is the most 
effective IFN-induced effector protein against LACV and has the potential to inhibit a wide range of 
RNA viruses in cell culture [73,74], but the murine homologue of human MxA, Mx2, is defective in 
most  inbred  mouse  strains  including  the  C57BL/6  mice  used  in  their  experiments  [71,75].  
MxA-transgenic  IFNAR−/−  mice  demonstrate  an  increased  survival  relative  to  IFNAR−/−  mice 
infected with LACV. However, only about 40% of the MxA-transgenic IFNAR−/− mice survived [74], 
which could be due to low levels of MxA expression in muscle cells and the non-uniform expression 
of MxA in the brain of the MxA-transgenic lines [74,76]. Thus, while MxA is the most effective  
IFN-induced effector protein against LACV, it is not solely responsible for anti-LACV activity. Even 
in the absence of Mx genes, the IFN response still delays bunyavirus replication [77–80] and PKR has Viruses 2011, 3                         
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been shown to be effective against BUNV [81] and RVFV lacking NSs (see below) [78]. Since most 
LACV  infections  in  humans  are  subclinical  with  only  a  small  proportion  of  infected  children 
developing encephalitis, the clinical outcome of LACV infection could be dependent on the degree of 
IFN production and the magnitude of IFN-induced antiviral effector proteins, including but not limited 
to MxA or PKR, in limiting peripheral LACV replication and virus spread to the CNS.  
RT-PCR analysis for some RNA polymerase II-dependent cellular genes that are constitutively 
expressed demonstrated a strong reduction in WT LACV infected cells, suggesting that LACV NSs 
may also affect host cell transcription similar to bunyamwera virus (BUNV) and RVFV [71,82–85]. 
Causing generalized inhibition of host cell transcription and thus gene expression is an effective way 
for viruses to block the production of IFNs and the up-regulation of IFN-induced antiviral effector 
proteins allowing the virus to overcome the host innate immune response. Most recently, LACV NSs 
was shown to act downstream of IRF-3 and specifically block RNA polymerase II transcription [72]. 
LACV NSs achieves this transcriptional block by inducing the degradation of RPB1, a subunit of RNA 
polymerase II [72]. Interestingly, transcriptional inhibition by LACV NSs is similar to the cellular 
DNA  damage  response.  Both  up-regulation  of  the  DNA  damage  response  gene  pak6  and 
phosphorylation of histone H2A.X, one of the first events in the DNA damage response, were induced 
by LACV NSs [72,86]. However, LACV NSs did not influence two other markers of the DNA damage 
response, p53 and BRCA1 [72]. When DNA is damaged, transcriptional arrest of RNA polymerase II 
occurs  and  triggers  the  degradation  of  RPB1  by  the  ubiquitin-proteasome  system  [87–91].  By 
removing RPB1 from the transcribing RNA polymerase complex, LACV NSs is able to disassemble 
the whole transcribing complex [72]. Therefore, since LACV activates the RIG-I pathway, LACV NSs 
counteracts the subsequent IFN gene transcription by shutting down RNA polymerase II dependent 
transcription and inhibiting the production of IFNs [72]. BUNV, which is closely related to LACV, is 
able to inhibit transcription in a similar manner through a different cellular target (Figure 3; Table 1). 
As with LACV, mutant BUNV lacking the NSs protein is impaired in its ability to shut off host cell 
protein synthesis in mammalian cells when compared to WT BUNV and is a strong inducer of IFN- 
via the dsRNA-activated transcription factors NF-B and IRF-3 [84,85]. The BUNV NSs inhibits 
transcriptional activation of the IFN- gene without affecting the activation of IRF-3 indicating that 
the  NSs  inhibitory  effect  is  downstream  of  the  primary  signaling  pathway  [92].  Using  another 
recombinant BUNV lacking the interaction domain of NSs with MED8, Leonard et al. found these 
viruses to have an impaired ability to inhibit host cell protein expression and an inability to inhibit the 
IFN response [84]. MED8 is an essential component of the Mediator transcription complex, which is 
involved in RNA polymerase II regulation by recruiting it to the promoter-bound preinitiation complex 
and interacting with the c-terminal domain (CTD)-serine-2 kinase P-TEFb [93–96]. Both serine 2 and 
serine  5  of  the  CTD  of  RNA  polymerase  II  are  the  main  regulators  of  polymerase  activity.  The 
phosphorylation  of  serine  2  is  critical  for  mRNA  elongation  and  3’-end  processing.  BUNV  NSs 
prevents  this  phosphorylation  suggesting  a  block  in  transition  from  initiation  to  elongation 
[84,85,97,98].  Therefore,  BUNV  NSs  inhibits  transcription  mediated  by  RNA  polymerase  II  by 
preventing the  phosphorylation  of  serine 2 of  RPB1 (Figure 3;  Table 1). LACV  NSs  specifically 
targets CTD-serine-2-phosphorylated RPB1 for degradation and therefore requires phosphorylation of 
serine 2. Thus, orthobunyaviruses counteract the IFN response by preventing the expression of IFNs 
using  their  NSs  proteins  to  specifically  shut  down  RNA  polymerase  II  dependent  transcription Viruses 2011, 3                         
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ensuring  the  antiviral  response  genes  are  selectively  shutoff.  Further  experiments  are  needed  to 
determine  if  the  orthobunyavirus  NSs  blocks  IFN  induction  solely  by  host  cell  transcriptional 
inhibition or whether NSs has a more specific anti-IFN mechanism.  
Figure  3.  Mechanisms  of  bunyavirus  NSs  proteins  targeting  RNA  polymerase  II 
transcription to counteract interferon gene expression. (A) The Mediator complex binds to 
the C-terminal domain (CTD) of RNA polymerase II holoenzyme. Transcription factors 
and  RNA  polymerase  associate  with  Mediator  and  allow  for  the  formation  of  the 
preinitiation complex. (B) Rift Valley fever virus (RVFV) NSs binds p44, a subunit of 
TFIIH,  preventing  the  assembly  of  newly  synthesized  TFIIH  or  recycled  TFIIH 
subcomplexes  [83].  RVFV  NSs  forms  nuclear  filamentous  structures  that  also  contain 
TFIIH subunits p44 and XPB [83]. Therefore, RVFV NSs prevents the assembly of the 
transcription  preinitiation  complex.  (C)  Bunyamwera  virus  (BUNV)  NSs  prevents  the 
phosphorylation of serine 2 of the CTD of RNA polymerase II. Phosphorylation of serine 2 
is  for  mRNA  elongation  and  3’-end  processing  suggesting  BUNV  NSs  inhibits  RNA 
polymerase  II  transcription  by  preventing  the  transition  from  initiation  to  elongation 
[84,85]. (D) La Crosse virus (LACV) NSs induces a DNA damage-like response triggering 
the degradation of RPB1 [72]. This mechanism specifically targets RPB1 from transcribing 
RNA polymerase and thus requires the phosphorylation of serine 2 on the CTD of RNA 
polymerase II [72].  
 
   Viruses 2011, 3                         
 
 
640 
4.2. Rift Valley Fever Virus (RVFV) 
Similarly, RVFV NSs inhibits host cell transcription [83], but through a distinct mechanism that 
results in NSs forming filamentous structures in the nucleus of infected cells [99]. Here, the block of 
cellular  RNA  synthesis  is  due  to  RVFV  NSs  targeting  TFIIH-dependent  transcription.  Yeast  
two-hybrid screening identified the p44 subunit of the TFIIH transcription factor as a target or binding 
partner of RVFV NSs and further experiments demonstrated that RVFV NSs interacts with p44 in a 
complex that also contains the XPB subunit of TFIIH [83]. Furthermore, both p44 and XPB subunits 
of  TFIIH,  along  with  RVFV  NSs,  are  main  components  of  the  nuclear  filamentous  structures. 
However, RVFV NSs does not inhibit the activity of TFIIH nor does it dissociate the TFIIH complex 
[83]. Le May et al. favor the hypothesis that RVFV NSs causes a dramatic decrease in cellular TFIIH 
concentration.  Upon  RVFV  infection,  NSs  is  translated  in  the  cytoplasm  and  binds  to  p44  to  be 
transported  to  the  nucleus.  Even  though  the  XPD/p44  interaction  is  stronger  than  the  NSs/p44 
interaction, NSs likely monopolizes this interaction due to its presence in large excess compared to p44 
and is likely the reason for the accumulation of XPD in the cytoplasm [83]. In the nucleus, NSs might 
prevent the assembly of newly synthesized TFIIH and/or recycled TFIIH subcomplexes (Figure 3; 
Table 1), because NSs is unable to target p44 when present in the core TFIIH or once p44 is interacting 
with XPD [83]. Two important results begin to elucidate the mechanism of RVFV NSs transcriptional 
inhibition. First, the time course of infection shows a concomitant decrease in TFIIH subunits p51, 
p62, and XPD with the synthesis of NSs and the formation of nuclear filament containing p44 and 
XPB. Second, the naturally avirulent Clone C13 of RVFV, which contains a deleted NSs16-198, 
replicates and produces viral proteins but does not lead to a decrease in TFIIH concentration or RNA 
synthesis, suggesting that other viral proteins do not affect the basal transcription machinery [83].  
The  general  inhibition  of  host  cell  transcription  by  RVFV  is  very  potent  and  begins  to  occur 
approximately 8 hours after infection [83]. However, the IFN-β gene is constitutively repressed in cells 
and is turned on as soon as a virus infects the cell. RVFV is able to inhibit IFN-β gene expression as 
early as 4 hours after infection [100]. The NSs of RVFV directly interacts with Sin3A associated 
protein 30 (SAP30), a component of Sin3A corepressor complexes and a partner of the transcription 
factor YY1 [100]. In uninfected cells, the SAP30 corepressor complex interacts with the constitutively 
repressed  IFN-β  promoter  at the  −90 position through its YY1 binding site. After  viral infection, 
binding of YY1 to its −122 site recruits CBP to the promoter region of the IFN-β gene resulting in  
IFN-β gene expression [100]. SAP30 colocalizes with RVFV NSs filament as early as 5 hours after 
infection and RVFV NSs interacts with YY1 of the IFN-β gene promoter as soon as 4 hours following 
infection.  RVFV  NSs  inhibits  IFN-β  gene  expression  by reinforcing  the  corepressor  complex  and 
preventing the recruitment of CBP to the IFN-β promoter (Table 1) [100]. Importantly, these studies 
demonstrate that YY1 and corepressors can influence many promoter regions. Therefore, RVFV NSs 
inhibits IFN-β early after infection by interacting with SAP30 then blocks IFN production later during 
infection by a generalized host cell transcriptional shutoff [83,100]. The early block of IFN-β may 
have evolved to inhibit early IFN-β that may occur before RVFV NSs is able to interfere with TFIIH 
since NSs is unable to interfere with already formed TFIIH complexes [83]. Furthermore, the authors 
speculate that genes whose promoters interact with SAP30 and/or YY1 could be sensitive to abnormal Viruses 2011, 3                         
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transcriptional regulation by RVFV NSs filaments and could explain some of the pathogenic effects 
due to RVFV, such as abortion.  
IFN antagonists are common among the bunyaviruses and all bunyaviral NSs proteins thus far 
(RVFV, LACV, BUNV, and sandfly fever Sicilian virus) have been shown to block transcriptional 
induction of IFN genes and cause cellular protein synthesis inhibition, but are unable to alter the level 
of  double-stranded  RNA-dependent  protein  kinase  (PKR)  [71,78,85,101–103].  However,  RVFV  is 
unique among the bunyavirus NSs proteins because it has the additional ability to degrade PKR, most 
likely by the proteasome (Figure 1; Table 1) [78]. Poliovirus is the only other example of a virus that 
has been shown to degrade PKR in a similar manner [104]. While RVFV NSs is the bunyaviruses  
non-structural protein capable of degrading PKR, members of both the hantaviruses and nairoviruses 
cleave the triphosphate group off their 5’ genomic end [66]. This 5’ triphosphate group is important 
since ssRNAs containing a short stem-loop structure have been shown to activate PKR [105] and some 
of these viruses remove this 5’ triphosphate group to avoid IFN induction via RIG-I [66].  
Bunyavirus  NSs  act  as  IFN  antagonists  by  quickly  and  efficiently  shutting  down  host  cell 
transcription by targeting RNA polymerase II or its preinitiation complex (Figure 3; Table 1), as is the 
case  for  RVFV  NSs  [72,83,84].  LACV  NSs  degrades  transcriptionally  active  RNA  polymerase II 
while BUNV likely prevents the transition of mRNA transcription from initiation to elongation while 
leading to the degradation of RNA polymerase II [72,84,85,106]. RVFV has similarities to both LACV 
and BUNV in that it degrades PKR and targets TFIIH, which is a component of the RNA polymerase 
II preinitiation complex. However, RVFV NSs also leads to a decrease in RNA polymerase I activity 
as  well  [83].  Although  BUNV  NSs  has  not  been  examined  for  inhibition  of  RNA  polymerase  I 
activities, this possibility is unlikely because of its close relation with LACV NSs and the specificity of 
LACV NSs for RNA polymerase II. The ability of RVFV to inhibit the IFN response by multiple 
mechanisms  and  prevent  IFN-β  induction  soon  after  infection  may  provide  several  insights  into 
bunyavirus virulence and pathogenesis. The multifaceted inhibition of IFN induction by RVFV may 
reflect its more severe disease relative to LACV and BUNV. For example, RVFV NSs has the ability 
to block the virus from being sensed by PKR, block early IFN-β production, and then lead to general 
host cell transcriptional shutoff providing ideal cellular conditions for RVFV replication to flourish 
and subsequently infect surrounding cells since IFN production has been blocked and the neighboring 
cells  have  not  achieved  an  antiviral  state.  Moreover,  while  it  has  not  been  demonstrated 
experimentally, RVFV NSs may target early IFN-β expression to counteract its detection by PKR, 
TLR3 or another viral sensor that signals through TRIF to quickly induce IFN-β. 
5. Alphaviruses 
The Alphavirus genus of the Togaviridae is composed of about 30 members that are grouped by 
geographic  distribution  into  Old  World  and  New  World  alphaviruses  [107].  Similar  to  the 
Bunyaviridae,  the  alphaviruses  can  infect  a  variety  of  invertebrate  and  vertebrate  hosts,  including 
humans, with most being transmitted by mosquitoes [108]. Infection of invertebrate vectors results in 
persistent,  lifelong  infection  and  viral  replication  without  adversely  affecting  the  host.  However, 
infection of susceptible vertebrate cells leads to rapid cytopathic effects and vertebrate hosts usually 
develop acute infection resulting in disease. Alphaviruses cause a wide range of disease with most Old Viruses 2011, 3                         
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World  alphaviruses  causing  arthritis  and  rash  illness  and  New  World  alphaviruses  leading  to 
encephalitis. However, the distinction of Old and New World alphaviruses based on disease outcomes 
is not clear and some Old World alphaviruses have been associated with neurologic disease; Sindbis 
virus (the prototype alphavirus) causes encephalomyelitis in mice and Ross River virus (RRV) and 
chikungunya virus (CHIKV) cause neurological disease in humans and equines [109].  
Alphaviruses are positive-strand RNA viruses with genomes of approximately 12 kb, encoding two 
polyproteins. The polypeptide encoded at the 5’ end of genome is composed of the nonstructural 
proteins (nsPs) 1, 2, 3, and 4 involved in viral replication as the nsP123 or nsP1234 precursor that 
function in a complex for viral negative-strand RNA synthesis. nsP123 is processed into its individual 
proteins and the nsPs function to replicate the viral genome [108]. The mature nonstructural proteins, 
together  with  nsP4  form  the  replication  complex.  Here,  nsP1  serves  as  the  methyltransferase  and 
guanylyltransferase  while  nsP2  has  a  papain-like  protease  domain  and  helicase  activity.  The  
RNA-dependent RNA polymerase is encoded as nsP4 [108]. Encoded downstream of the replicase is 
the  second  polyprotein,  which  contains  the  structural  proteins:  the  capsid  protein  and  envelope 
glycoproteins [108]. As with many viruses in mammalian cells, alphavirus replication usually results in 
translational shutoff of the host cell leading to the suppression of innate immunity [110]. However, this 
host protein synthesis shutoff alone is not sufficient for alphaviruses to achieve a productive infection 
[111]. New World and Old World alphaviruses have been demonstrated to use different mechanisms to 
achieve  host  cell  translational  shutoff,  with  Old  World  alphaviruses  using  nsP2  and  New  World 
alphaviruses utilizing the capsid protein. However, recent evidence suggests New World alphaviruses 
may have additional methods to counteract the host IFN response.  
5.1. New World Alphaviruses 
EEEV and VEEV (New World alphaviruses) shut off host cell transcription, which involves the 
capsid protein, through mechanisms that are still unclear. There is evidence that the capsid protein’s 
activity  is  associated  with  defects  in  type  I  IFN  and  ISG  induction,  most  likely  due  to  global 
transcriptional shutoff [16,17,112]. However, recent experiments using VEEV replicons demonstrated 
that VEEV disrupts the cellular response to IFNs by mechanisms that do not require the viral capsid 
[111]. Since these replicons do not contain any structural genes and cells infected with these replicons 
do not activate STAT1, it is likely that the expression of a viral nonstructural protein is responsible for 
this  shutoff.  The  inhibition  of  STAT1  activation  prevents  the  nuclear  localization  of  STAT1  and 
subsequently  results  in  decreased  STAT1-dependent  gene  transcription  [111].  Global  host  cell 
transcriptional and translational shutoffs probably work synergistically with STAT1 inhibition; it is 
likely that host shut off is not required for the inhibition of JAK/STAT signaling by VEEV replicon 
expression.  The  STAT1  antagonizing  mechanism  decreases  STAT1  phosphorylation  (Figure  1;  
Table 1) but does not affect the overall STAT1 levels and the IFNAR complex is still able to activate 
Jak1, Tyk2 and STAT2, indicating that the mechanism is specific for STAT1 [111]. The mechanism(s) 
of the block in STAT1 phosphorylation by VEEV has not been elucidated, but Simmons et al. [111] 
suggest  that  a  viral  nonstructural  protein  could  bind  STAT1  or  the  receptor  complex  preventing 
STAT1’s phosphorylation by JAK kinases and/or its association with the IFNAR. Viruses 2011, 3                         
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5.2. Old World Alphaviruses 
Recently,  it  has  been  shown  that  JAK-STAT  signaling  is  inhibited  by  the  CHIKV  nsP2 
overexpression. Notably this is the first time that an alphavirus nsP2 alone has been shown to be 
sufficient  for  this  inhibition  [113].  Previously,  it  was  known  that  IFNAR-dependent  type  I  IFN 
signaling was required to limit CHIKV replication in animals and IFN- inhibited CHIKV replication 
in  mice  when  administered  prior  to,  but  not  after,  CHIKV  infection  [114].  As  with  VEEV,  IFN 
antagonism by CHIKV is independent of host cell shutoff since cells treated with cycloheximide, an 
inhibitor  of  cellular  protein  synthesis,  did  not  have  altered  JAK-STAT  signaling  nor  reduced 
endogenous levels of STAT1 [111,113]. Additionally, the authors suggest that nsP2 is such a potent 
inhibitor of STAT1 nuclear translocation (Figure 1; Table 1), any other contributory activity by other 
viral  proteins  may  not  be  needed  to  establish  a  productive  infection  and  STAT1  up-regulation  in 
CHIKV-infected cells is prevented by the inhibition of JAK-STAT signaling [113]. Recently, CHIKV 
was shown to strongly induce the transcription of IFN and ISGs via IPS-1; however, these mRNAs are 
not translated into protein, as there is a widespread block of cellular, but not viral, translation [115]. 
Although  the  viral  factor(s)  responsible  for  this  translation  block  are  currently  unknown,  it  may 
represent  a  novel  mechanism  of  translational  block  since  it  occurs  independently  of  PKR  [115]. 
Furthermore, a late shutoff of host cell RNA synthesis induced by CHIKV prevents the transcription of 
IFN- and ISGs [115].  
A  mutation  of  a  conserved  proline  in  CHIKV  nsP2  at  position  718  prevented  a  block  of  
IFN--induced STAT1 nuclear translocation. Similar results were obtained for SINV replicons with a 
mutation at a conserved proline at position 726 suggesting these viruses use similar mechanisms to 
block the JAK-STAT pathway [113]. These experiments were based on the previously characterized 
mutation of P726 in SINV that resulted in noncytopathic RNA replication [116] and attenuated virus 
growth associated with high IFN production [116,117]. More recent studies confirmed that infection 
with  WT  SINV  led  to  minimal  up-regulation  of  transcription  from  genes  driven  by  the  IFN- 
promoter.  However,  IRF3  still  dimerized,  translocated  to  the  nucleus  and  bound  DNA  [118].  In 
contrast, a noncytopathic SINV (39nc) did not block the release of IFN-/. This IFN production was 
dependent on the presence of TBK1 and was likely associated with activation of the NF-B-dependent 
PRDII  promoters  (Table  1)  [118].  Additionally,  MDA5  is  partially  responsible  for  IFN  induction  
by  SINV  39nc  and  is  likely  activated  by  the  high  levels  of  dsRNA  produced  during  alphavirus 
replication [118,119].  
A  mutant  Semliki  forest  virus  (SFV)  with  a  single  point  mutation  in  the  RRR  (wt)  nuclear 
localization within nsP2 has provided more evidence for the alphavirus nsP2 as a potent and specific 
inhibitor of the IFN response. This mutant SFV replicates comparably to wt SFV and induces similar 
levels of global transcription and translational shutoff in the cell. However, it induces significantly 
more type I IFN, indicating that the differences in cytokine responses are not solely due to the global 
suppression of the host cell [120]. Although the precise mechanism(s) of this IFN antagonism have not 
been determined, the nuclear translocation of IFN-inducing transcription factors IRF-3 and NF-B is 
unaffected,  suggesting  that  SFV  nsP2  suppresses  type  I  IFN  induction  at  some  point  beyond  the 
nuclear translocation of these transcription factors [120]. However, TNF- levels were also increased 
in mutant SFV infected cells indicating a non-IFN-specific effect on host cell gene expression. To Viruses 2011, 3                         
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explain this phenomenon, Breakwell et al. suggest that nsP2 could inhibit larger groups of genes by 
blocking  the  activity  of  a  particular  transcription  factor  [120].  One  possible  explanation  of  the 
inhibitory effects of nsP2 on the host cell responses could stem from nsP2’s papain-like protease 
domain. In the replication of SFV, this domain of nsP2 processes the nsp1234 polyprotein and leads to 
the viral replicase complex [121,122]. Since nsP2 translocates to the nucleus, this protease activity 
could be maintained and result in the cleavage of cellular transcription factors (Table 1) similar to that 
seen in the rhinovirus 3C protease [123]. Further experiments using constructs of SFV nsP2 with 
deletion  or  mutation  of  the  papain-like  protease  domain  could  be  used  to  explore  this  possible 
mechanism of inhibitory action.  
More recent studies of SINV and RRV with mutations in the nsP1/nsP2 cleavage domains of nsP1 
have demonstrated a role for nsP1 in modulating type I IFN induction independently of host cell 
shutoff [124]. In contrast to the studies of SFV in which IRF-3 were unaffected, these SINV and RRV 
mutants affected IRF-3 (Table 1) suggesting different mechanisms of IFN antagonism [124]. Even 
though these inhibitory mechanisms have not been defined, these observations support a model in 
which alphavirus nsPs play a major role in modulating type I IFN induction independent of host cell 
shutoff, and likely by using multiple and distinct mechanisms.  
6. Flaviviruses 
Flaviviruses encode seven  nonstructural proteins  (NS1, NS2A, NS2B,  NS3, NS4A, NS4B, and 
NS5)  with  several  of  these  nonstructural  proteins  involved  in  the  flaviviral  replication  complexes  
[125–128].  Some  of  these  flaviviral  nonstructural  proteins  are  involved  in  counteracting  the  IFN 
response and may have evolved separately as the flaviviral lineages diverged early in the evolution of 
the genus. Of the 75+ viruses within the Flavivirus genus, approximately 40 are mosquito-borne, 16 
are tick-borne, and 18 have no known vector [129]. Furthermore, the three evolutionary lineages can 
be  separated  by  genomic  sequence  analysis  and  base  substitution  rates  [130].  While  NS5  is  the  
main virulence factor for tick-borne flaviviruses [131,132], mosquito-borne flaviviruses use NS5 as 
well as other non-structural proteins to inhibit the IFN response (NS2A, NS2B, NS3, NS4A, and 
NS4B) [133–136].  
6.1. Tick-Borne Flaviviruses 
The  tick-borne  encephalitis  serocomplex  of  flaviviruses  includes  tick-borne  encephalitis  virus 
(TBEV), Powassan, and Kyasanur Forest disease virus. Members of this serogroup are an emerging 
arboviral  threat  due  to  the  high  morbidity  and  mortality  rates  associated  with  disease,  including 
encephalitis, meningitis, and/or hemorrhagic fever. TBEV is transmitted by Ixodes ticks and, more 
rarely, in infected milk (goat, sheep, and cow milk) and aerosols [137]. TBEV is endemic in Russia, 
Czech Republic, Austria, Poland, Serbia and Montenegro [138]. However, in recent years, TBEV has 
spread to Italy, Denmark, Scandinavia, and Greece demonstrating the emergence potential of TBEV 
and other related tick-borne flaviviruses [138–140].  
Langat virus (LGTV), a member of the TBE serocomplex, is sensitive to the antiviral effects of IFN 
when added exogenously prior to infection in VERO cells [132], which can respond to but not produce 
IFNs  [141].  However,  when  LGTV  infection  occurred  prior  to  IFN  addition,  phosphorylation  of Viruses 2011, 3                         
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STAT1, STAT2, Tyk2, and Jak1 were all inhibited [132], suggesting that LGTV must establish a 
productive infection to counteract the IFN response. In these LGTV infected cells, levels of STAT1 
and  STAT2  were  unchanged  but  the  phosphorylation  of  STAT1  in  response  to  IFN-  or  IFN- 
stimulation, as well as STAT2 in response to IFN-, were inhibited [132]. Expression of individual 
LGTV nonstructural proteins identified NS5 as the direct IFN antagonist and demonstrated its ability 
to suppress IFN-stimulated STAT1 phosphorylation by itself (Figure 1; Table 1). This inhibition of 
JAK-STAT signaling is likely due to the direct association of NS5 with IFNAR2 and/or IFNGR1, 
allowing  for  early  virus  replication  in  individual  cells  [132].  The  direct  association  of  NS5  with 
IFNAR2 subunits suggests a host factor for proper targeting of NS5 to the plasma membrane where the 
receptors are located.  
A  yeast  two-hybrid  screen  using  TBEV  NS5  against  a  human  brain  cDNA  library  identified 
scribble  (hScrib)  as  a  binding  partner  [131].  hScrib  is  in  the  LAP  (leucine-rich  repeats  and 
PSD/Dlg/ZO-1 [PDZ]) family of proteins [142] and plays a role in T-cell polarity, which is required 
for  T-cell  activation  and  antigen  presentation  [142].  Furthermore,  hScrib  is  thought  to  stabilize  
cell-to-cell contacts involving E-cadherin at the membrane of polarized mammalian cells, supporting it 
as a potential cellular chauffeur of NS5 to the cell membrane  [143]. TBEV NS5 colocalizes with 
hScrib and E-cadherin at cell-to-cell contacts in mammalian cells. Importantly, hScrib knockdown in 
NS5 expressing cells rescued phosphorylation and nuclear translocation of STAT1 [131]. When direct 
binding  of  the  methyltransferase  domain  of  TBEV  with  the  fourth  PDZ  domain  of  hScrib  was 
disrupted  by  a  binding-defective  mutant  NS5,  the  nuclear  phosphorylated  STAT1  was  partially 
restored and NS5 was unable to accumulate at the cell surface [131].  
Among the TBE virus serogroup, NS5 has 80–90% amino acid identity, suggesting the conservation 
of the IFN antagonist mechanism by NS5 within the serogroup. However, the interaction of LGTV 
NS5  with  hScrib  is  still  unresolved.  Although  it  has  been  suggested  that  the  mechanism  of  IFN 
antagonism by NS5 of the serogroup is conserved among the flaviviruses, experimental and amino acid 
identity suggest a similar yet different mechanism(s) among the mosquito-borne flaviviruses. The NS5 
highly conserved amongst members of the TBE serogroup and shares 60% amino acid identity with the 
NS5  of  WNV  and  DENV-2.  The  divergence  of  tick-borne  and  mosquito-borne  flaviviruses  NS5 
reflects the phylogenetic divergence of these groups and their strategies to counteract host IFN.  
6.2. Mosquito-Borne Flaviviruses 
The mosquito-borne flaviviruses are arguably the best-known arboviruses and include WNV, YFV, 
and DENV. The most widespread of arboviruses, DENV is responsible for 50 million to 100 million 
infections annually with almost half of the world’s population living in an at-risk area. There are four 
DENV  serotypes  (DENV1-4)  and  infection  typically  results  in  a  flu-like  illness  with  life-long 
immunity to that serotype. However, infection with another  serotype can lead to the  more severe 
dengue hemorrhagic fever or dengue shock syndrome. The increase in vascular permeability is perhaps 
the most serious complication of dengue hemorrhagic fever or dengue shock syndrome, and it has been 
suggested that infected immature dendritic cells overproducing matrix metalloproteinase (MMP)-9 are 
responsible for this permeability [144]. Thus, the cross-reactivity among DENV serotypes and the Viruses 2011, 3                         
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possible role of MMP-9 in severe DENV disease underscores the importance of understanding these 
aspects of host virus interactions as they will guide the development of therapeutics and vaccines.  
Cytoplasmic DENV NS5 expressed alone is sufficient to efficiently inhibit the IFN-, but not IFN- 
response. More specifically, cells expressing DENV NS5 alone inhibited STAT2, but not STAT1, 
phosphorylation without affecting levels or phosphorylation of Tyk2 or surface expression of IFNAR2 
[134]. Since STAT2, but not STAT1 or Tyk2, coimmunoprecipitates with NS5, the phosphorylation 
and activation of STAT2 is prevented by either direct or indirect association of NS5 and preventing 
STAT2’s interaction with Tyk2 [134]. Interestingly, when cells are infected by DENV or replicons 
expressing all the nsPs, STAT2 levels are decreased and this decrease requires intact proteasome and 
ubiquitinating activities [133,134]. A protease cleavage signal upstream of the N-terminus of DENV 
NS5  is  required  for  STAT2  to  be  targeted  for  degradation.  However,  the  protease  required  for 
maturation of NS5 with concomitant degradation of STAT2 does not seem to be specific (Figure 1; 
Table 1). Therefore, the NS5 precursor being cleaved to mature NS5 is required for the degradation of 
STAT2 [133,134]. The mechanism of STAT2 degradation is still unclear beyond the involvement of 
the  proteasome  and  ubiquitination  [133,134].  Since  DENV  NS5  prevents  IFN  signaling,  the 
degradation of STAT2 may provide an additional advantage to the virus. 
While DENV, LGTV, and TBEV block JAK-STAT signaling by direct binding to one of the main 
signaling  components,  JEV  NS5  targets  protein  tyrosine  phosphatases  (PTPs)  to  exert  their  IFN 
antagonist  effect  [145].  PTPs  are  one  of  several  cellular  negative  regulators  of  the  JAK-STAT 
signaling pathway along with protein inhibitors of activated Stats (PIAS) and suppressor of cytokine 
signaling (SOCS) proteins. JEV NS5 effectively blocks STAT1 and Tyk2 phosphorylation (Figure 1; 
Table 1) and sodium orthovanadate, a broad spectrum inhibitor of PTPs, abolishes the block in STAT1 
and Tyk2 phosphorylation [145]. The use of specific PTP inhibitors did not block the effect of JEV 
NS5, suggesting the responsible PTP is probably an unidentified cellular PTP [145]. JEV NS5 itself 
could act as a PTP but sequence alignment with PTPs suggests that JEV NS5 does not possess PTP 
activity. Furthermore, neither the methyltransferase or polymerase activity of JEV NS5 alone appears 
to be responsible for counteracting JAK-STAT signaling [145]. Therefore, JEV NS5 does not block 
the  induction  of  IFN,  but  activates  a  cellular  PTP  to  dephosphorylate  STAT1  and  Tyk2,  thus 
preventing the nuclear translocation of STAT1.  
DENV NS5 is not the only nonstructural protein encoded by DENV that has IFN antagonizing 
activities. Individual expression of DENV NS2A, NS4A, and NS4B enhanced replication of IFN-/ 
sensitive Newcastle disease virus [135]. Furthermore, each of the three nonstructural proteins inhibited 
activation of two different ISRE promoters, albeit NS2A and NS4A caused less inhibition than NS4B. 
When all three of these nonstructural proteins were coexpressed, IFN signaling was almost completely 
abrogated suggesting a synergistic and cooperative IFN counteraction by these viral proteins [135]. As 
with the ability of DENV NS5 to degrade STAT2, NS4A/NS4B cleavage is required for the anti-IFN 
activity of NS4B. Additionally, NS4B’s localization and insertion into the ER membrane are required 
for  NS4B  anti-IFN  activity  since  the  absence  of  a  signal  peptide  renders  NS4B  nonfunctional  
(Table 1). The N-terminal 2K segment of DENV NS4B is not involved in the anti-IFN activity, as it 
can be replaced by another signal peptide without altering NS4B functionality [135].  
The precise mechanism of DENV NS4B has not been determined, although it does prevent the 
nuclear  translocation  of  STAT1  in  response  to  IFN-  [135].  Interestingly,  Muñoz-Jordán  et  al. Viruses 2011, 3                         
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determined the amino acids in region 77 to 125 are required for DENV NS4B to antagonize IFN and 
within this region, amino acids 77 to 103 are predicted to be cytoplasmic anchored by the first and 
second transmembrane domains of NS4B [135]. Thus, it would be plausible for these amino acids to 
interact  with  cellular  components  in  the  cytoplasm  involved  in  IFN-signaling.  However,  further 
experiments will be needed to elucidate the interactions of this cytoplasmic domain. Other mosquito-
borne flaviviruses, namely YFV and WNV, have conserved NS4B to inhibit the JAK-STAT pathway, 
suggesting a converging mechanism of the NS4B proteins among the mosquito-borne flaviviruses.  
Because many viruses become sensitive to the IFN response when their IFN antagonist’s function is 
disabled, these nonstructural proteins are promising targets for the development of attenuated viral 
vaccines. The introduction of the NY 99 strain of WNV (WNVNY99) has gained considerable attention 
due to its recent emergence and rapid spread in the United States. While WNVNY99 is highly virulent, 
its close relative, Kunjin virus (WNVKUN), exhibits a highly reduced pathogenesis in humans, animals, 
and birds. Even though these two viruses differ greatly in their virulence, they are more than 98% 
identical in their amino acid sequences and express all seven flavivirus nonstructural proteins, making 
WNVKUN  a  possible  candidate  for  the  development  of  a  WNV  vaccine  [146].  Therefore,  the 
differences  in  virulence  are  likely  due  to  mutations  in  WNV  virulence  factors.  Furthermore, 
immunization with WNVKUN completely protects mice from a lethal challenge with WNVNY99 [147]. 
However, further attenuation of WNV would be ideal for a safe, live WNV vaccine. One example of 
further attenuation in the context of WNV vaccine candidates is a mutation in NS2A, which is a major 
suppressor  of  IFN-  transcription.  A  single  amino  acid  mutation  in  NS2A  (alanine  to  proline  at 
position 30; A30P) prevented this suppression of IFN- and induced IFN- transcription ~6–7-fold 
more efficiently than WT WNVKUN [136]. Although WNVKUNNS2/A30P did not grow or spread as 
well as WT WNVKUN in IFN-/ producing cell lines, the levels of IFN-/ were higher in the cell 
culture supernatant of those cells infected with the mutant virus [148]. When mice were immunized 
with WNVKUNNS2/A30P, a strong humoral response was induced, indicating that this mutation did not 
compromise  the  magnitude  of  immune  response  mounted  against  the  virus.  Furthermore,  the 
immunization provided complete protection to all of the mice against peripheral challenge of a lethal 
dose of WNVNY99 [148]. The mutant virus was also attenuated after intracranial inoculation, which is 
not surprising since encephalitic viral infections induce IFN responses in the brain. While the LD50 of 
WNVKUNNS2/A30P was almost 100,000 fold higher than WNVKUN after peripheral inoculation, the 
difference in LD50s of the two viruses was less profound following intracranial inoculation  [148]. 
These studies provide promising evidence for the further attenuation of vaccine candidate viruses by 
targeting  their  IFN  antagonist  nonstructural  proteins,  but  also  demonstrate  the  need  to  better 
understand the interactions of arboviruses and the host immune system, particularly in the CNS.  
7. Conclusions 
The mammalian IFN response is an important antiviral defense mounting both innate and adaptive 
immune responses to control and clear viral infections. However, better models of these host-virus 
interactions  need  to  be  developed.  As  previously  mentioned,  most  inbred  strains  of  mice  have 
defective Mx2, the homologue of human MxA, which is the most effective antiviral effector protein 
described in humans against LACV. Further work is needed to evaluate the efficacy of interferon Viruses 2011, 3                         
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responses  in  mouse  models.  Moreover,  parallel  experiments  in  vitro  in  human  cells  may  help  in 
determining the reliability or transferability from mouse models to humans of such findings. While 
many  large-scale  factors,  e.g.,  climate  change,  population  growth,  travel,  and  urbanization,  have 
contributed to the emergence and re-emergence of many arboviruses, perhaps one of the most constant 
features of emerging arboviruses is their widespread use of virus-encoded nonstructural proteins to 
counteract the IFN response. As more viral IFN antagonists are being identified and characterized, it is 
clear  that  many  viruses  use  a  variety  of  mechanisms  to  counteract  the  host-immune  response. 
Furthermore, these studies have provided more experimental evidence to support the hypothesis that 
severity of disease associated with many arboviral infections correlates with the ability of the virus to 
counteract the IFN response. The ability of some viruses, like RVFV, to counteract multiple pathways 
(Table 1) in its detection or in the induction or signaling of IFNs likely enhances the pathogenicity of 
the virus. A better understanding of host-virus interactions and the viral determinants responsible for 
disease outcome and virus emergence and re-emergence are a prerequisite for the development of 
attenuated viral vaccines and anti-viral therapies that will both control the spread of these emerging 
infections and lead to better prophylaxis and health outcomes. 
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